Up­dat­ed: Al­ny­lam re­in­forces APOL­LO-B patisir­an da­ta be­fore head­ing to the FDA

Weeks af­ter un­cork­ing some most­ly pos­i­tive da­ta for patisir­an in transthyretin-me­di­at­ed (AT­TR) amy­loi­do­sis with car­diomy­opa­thy, Al­ny­lam is bol­ster­ing its pack­age with new ex­plorato­ry and sub­group …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER